Gastrointestinal
Esophageal:
CIRB #2008-031C/RTOG #R0436: A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients with Esophageal Cancer who are Treated without Surgery
IRB #H-28136/ACOSOG #Z4051: A Phase II Study of Neoadjuvant Therapy with Cisplatin, Docetaxel, Panitumumab plus Radiation Therapy Followed By Surgery in Patients with Locally Advanced Adenocarcinoma of the Distal Esophagus (temp closure 9/1/09)
Cholangiocarcinoma:
IRB #H-28930/SWOG #S0809: A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed by Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)(Pending)
Colon/Rectal:
IRB #2006-065C/CTSU #N0147: A Randomized Phase III Trial of Oxaliplatin (OXAL) plus 5-Fluorouracil (5-FU)/ Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer (temporary suspension of accrual for patients 70 or older)
IRB #2006-035C/CTSU #C80405: A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum
IRB #2007-038C/SWOG #S0600: A Phase III Trial of Irinotecan-Based Chemotherapy + Cetuximab or Bevacizumab as Second-Line Treatment for Patients with Metastatic Colorectal Cancer who Progressed on Bevacizumab with either FOLFOX, OPTIMOX, or XELOX
DOR Biopharma/WIRB #pend: A Phase 1/2 Study to Evaluate Escalating Doses of DOR201 [Entericcoated Oral Beclomethasone Dipropionate (BDP)] For Prevention of Signs and Symptoms of Acute Enteritis in Patients with Rectal Cancer Treated with Combined Chemotherapy and Radiation Therapy (pending)
Carcinoid:
IRB #pend/SWOG #S0518: Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients (Pending)
Pancreas:
IRB #H-27656 / SWOG #S0727: A Phase I and Randomized Phase II Trial of Gemcitabine + Erlotinib + IMC-A12 vs. Gemcitabine + Erlotinib as First-Line Treatment in Patients with Metastatic Pancreatic Cancer
